Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Neurocrine biosciences, inc. symbols : TAK save search
Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder
Published: 2024-04-23 (Crawled : 13:30) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: -0.11%
H: 0.0%
C: 0.0%
NBIX | News 4 | $138.91 -0.84% -0.85% 880K
|
Health Technology
|
| O: 5.49%
H: 2.84%
C: -0.65%
nbi-1065 positive for
Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2023 Financial Results and Provides Financial Expectations for 2024
Published: 2024-02-07 (Crawled : 12:00) - prnewswire.com
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: 0.07%
H: 0.42%
C: 0.07%
NBIX | News 4 | $138.91 -0.84% -0.85% 880K
|
Health Technology
|
| O: -5.57%
H: 6.04%
C: 0.96%
financial results
Neurocrine Biosciences Reports Second Quarter 2023 Financial Results and Raises 2023 INGREZZA Sales Guidance
Published: 2023-08-01 (Crawled : 15:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: -2.23%
H: 2.28%
C: 1.34%
NBIX | News 4 | $138.91 -0.84% -0.85% 880K
|
Health Technology
|
| O: 0.6%
H: 1.95%
C: 0.92%
sales ingrezza financial results
Global CNS Therapeutics Strategic Business Report 2023: Burgeoning Global Aging Populace, Longer Life Expectancy to Drive CNS Demand
Published: 2023-06-30 (Crawled : 23:00) - prnewswire.com
ALKS | $24.66 1.65% 1.62% 1.7M
|
Health Technology
| Email alert
Add to watchlist
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
| Email alert
Add to watchlist
NBIX | News 4 | $138.91 -0.84% -0.85% 880K
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
| Email alert
Add to watchlist
UCBJY | $65.26 -4.38% 5.9K
|
Manufacturing
| Email alert
Add to watchlist
UCBJF | $128.725 -39.66% 750
|
Health Technology
| Email alert
Add to watchlist
AZNCF | News | $140.3 -4.19% 1.5K
|
Health Technology
| Email alert
Add to watchlist
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
| Email alert
Add to watchlist
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
| Email alert
Add to watchlist
NVSEF | News | $96.0 6.88% 52K
|
Health Technology
| Email alert
Add to watchlist
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
| Email alert
Add to watchlist
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
| Email alert
Add to watchlist
AZN | News | $71.175 0.46% 0.46% 6.1M
|
Health Technology
| Email alert
Add to watchlist
TEVJF | News | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
| Email alert
Add to watchlist
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
| Email alert
Add to watchlist
report business life global therapeutics
Neurocrine Biosciences Reports First Quarter 2023 Financial Results
Published: 2023-05-03 (Crawled : 12:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: 0.36%
H: 0.57%
C: 0.18%
VYGR | News | $7.57 -1.05% -1.06% 310K
|
Health Technology
|
| O: 5.76%
H: 6.4%
C: 5.04%
NBIX | News 4 | $138.91 -0.84% -0.85% 880K
|
Health Technology
|
| O: 3.43%
H: 0.92%
C: -7.83%
financial results
Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2022 Financial Results and Provides Financial Expectations for 2023
Published: 2023-02-06 (Crawled : 13:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: -0.94%
H: 0.51%
C: -0.13%
VYGR | News | $7.57 -1.05% -1.06% 310K
|
Health Technology
|
| O: -1.11%
H: 3.87%
C: 0.5%
NBIX | News 4 | $138.91 -0.84% -0.85% 880K
|
Health Technology
|
| O: -5.23%
H: 6.35%
C: 0.71%
financial
Neurocrine Biosciences Reports Third Quarter 2022 Financial Results and Raises 2022 INGREZZA Sales Guidance
Published: 2022-11-01 (Crawled : 12:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: 0.68%
H: 1.05%
C: -0.23%
NBIX | News 4 | $138.91 -0.84% -0.85% 880K
|
Health Technology
|
| O: -0.1%
H: 7.37%
C: 3.79%
sales ingrezza financial results
Neurocrine Biosciences Reports First Quarter 2022 Financial Results and Reiterates 2022 Financial Guidance
Published: 2022-05-04 (Crawled : 12:00) - prnewswire.com
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
NBIX | News 4 | $138.91 -0.84% -0.85% 880K
|
Health Technology
|
| O: -0.04%
H: 0.97%
C: -2.97%
results
Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2021 Financial Results and Provides Financial Expectations for Fiscal 2022
Published: 2022-02-11 (Crawled : 13:00) - prnewswire.com
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: -0.07%
H: 0.0%
C: 0.0%
NBIX | News 4 | $138.91 -0.84% -0.85% 880K
|
Health Technology
|
| O: 1.21%
H: 0.0%
C: 0.0%
financial results ces report bioscience results
Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2021 Net Product Sales Results and Future Program Milestones
Published: 2022-01-06 (Crawled : 00:00) - biospace.com/
PPRUF | News | $340.0 37.56% 1.5K
|
Consumer Non-Durables
|
| O: 2.64%
H: 0.0%
C: -0.39%
PPRUY | News | $33.79 -0.11% 360K
|
Manufacturing
|
| O: -0.99%
H: 0.0%
C: -1.16%
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: 1.0%
H: 0.0%
C: 0.0%
NBIX | News 4 | $138.91 -0.84% -0.85% 880K
|
Health Technology
|
| O: 0.24%
H: 0.0%
C: 0.0%
sales bioscience milestone
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.